Report says CMOs without U.S. facilities risk being left out of 'hot' market

A new report from CPhI of the U.S. market says that international API and drug manufacturers need to consider investing in U.S. manufacturing sites as drugmakers look to source products in the U.S. because of concerns over quality in some other countries. It says that "for contract manufacturing, the U.S. market is now as hot as it has been at any other time in the last 10 years, with a scramble occurring across international players to get a domestic manufacturing foothold in the market," especially in specialized areas like biologics. Release

Suggested Articles

Lupin pulled one lot of lisinopril after finding the wrong tablets in some bottles. Sun Pharma yanked clonazepam bottles on contamination fears.

The U.S. is slamming the brakes on its $765 million loan to Kodak amid insider trading allegations and questions about its fitness for the job.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan